| Today's Big NewsApr 28, 2023 |
|
May 1 - 3, 2023 | Jersey City, NJ
Explore In-Depth Discussions Across 3 Tracks Dedicated to Medical Affairs Professionals. Last chance to register! Don’t miss out,register today.
|
|
| By Max Bayer Gilead accelerated R&D spending in the first quarter, notching a 25% increase versus the first quarter of 2022. Company executives attributed the rise in part to ramping up a bevy of ongoing mid-to-late-stage trials. |
|
|
|
By Gabrielle Masson In a day chock-full of Big Pharma earning calls and accompanying pipeline culls, Amgen is no exception, slicing both of its mid-stage lupus programs for futility. |
By Max Bayer The middle of Merck & Co.’s clinical batting order took center stage on the company’s first-quarter earnings call, including a phase 2 HIV combo therapy that once again returned to the lineup. |
By Gabrielle Masson Sanofi's multiple sclerosis med tolebrutinib may be under a partial FDA clinical hold after reports of liver injury in a handful of phase 3 studies, but that is not stopping the French pharma from collecting some data to make the case for efficacy and safety. |
By Annalee Armstrong Analysts are desperately trying to read the tea leaves comparing Eli Lilly’s Alzheimer’s med and Eisai/Biogen’s Leqembi before the mug is cool, but executives say there are “lots of ways for donanemab to win.” |
By Nick Paul Taylor Joe Jimenez’s VC fund has ponied up $10 million to try to crack a nut that defeated a who’s who of top drug developers. The outlay gives the fund, Aditum Bio, near-global rights to a BTK inhibitor, with a twist, that is in development in autoimmune diseases including rheumatoid arthritis. |
By Max Bayer,Gabrielle Masson Bristol Myers Squibb came in hot with one heck of a news bomb, announcing Thursday that CEO Giovanni Caforio, M.D., plans to retire in November after eight years at the helm. |
By Kevin Dunleavy On a day when Eli Lilly revealed stellar trial results for its obesity treatment tirzepatide and spent more than half of its quarterly earnings presentation discussing the drug's prospects, there was a disquieting side note. Using tirzepatide might be a lifetime decision. |
By Conor Hale The clinical testing giant plans to acquire the Baltimore-based Haystack for its technology to detect minimal residual disease, by catching the early signs of a solid tumor’s recurrence by sifting out small pieces of cancer DNA floating in the bloodstream. |
By Kevin Dunleavy With its next-generation pneumococcal vaccine, Pfizer has been playing catch-up with Merck in the indication’s key age group—infants. Thursday, Pfizer got to the finish line 10 months after its rival, but with a shot that offers more protection. |
By Heather Landi Walmart Health continues to grow its health clinic footprint with an expansion into Oklahoma next year. This is in addition to already-announced plans to move into Missouri and Arizona in 2024. |
By Angus Liu The FDA has delayed a decision on Daiichi Sankyo's acute myeloid leukemia drug quizartinib. Meanwhile, the company's Enhertu tripled sales in fiscal year 2022. Merck and Glenmark settled a pay-for-delay case around Zetia. And more. |
By Teresa Carey This week on "The Top Line," we're launching a mini-series on Narcan the nasal spray. It is the first naloxone product to be approved for use without a prescription. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we're launching a mini-series on Narcan the nasal spray. It is the first naloxone product to be approved for use without a prescription. |
|
|---|
|
|
|
July 18-19, 2023 | Jersey City, NJ
Hear the latest industry trends from leaders in the field, and developed with input from our esteemed advisory board, to ensure you have a sound plan for your company, brands, and yourself. Save $500 when you Register Today!
|
|
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| Whitepaper How can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| Whitepaper The preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
| Whitepaper We’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
| Whitepaper How advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
| WhitepaperThis paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
